Compare Tidewater Inc (TDW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Tidewater Inc trades at $91.5 (market cap $4.46B), while Vertex Pharmaceuticals Incorporated trades at $528.02 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 29.8× Tidewater Inc's market cap. Which is the better fit depends on your goals.
| TDW | VRTX | |
|---|---|---|
Market Cap | $4.46B | $132.79B |
Sector | Utilities | Health |
52-Week High | $91.20 | $529.65 |
52-Week Low | $47.29 | $376.62 |
Enterprise Value | $4.50B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $82.84, up 1.56% today, with a bullish technical signal from moving averages and strong support at $81. The company reported Q2 2026 EPS of $0.43, beating estimates, but has missed expectations in recent quarters. Revenue for 2025 was $1.35B with a net income margin of 18.34%, though 2026 projections show a decline to $1.3B and lower margins. Analyst consensus is mixed with 26.92% buy ratings, while institutional holdings saw increases from First Trust Advisors and Bank of New York Mellon in 2026.
Outlook: TDW benefits from operational strength and bullish technicals, but earnings misses and margin compression pose risks. Investors should weigh solid cash flow against competitive and macroeconomic headwinds in the oil and gas sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
